Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
A CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
A Coverage Bootstrap CRISPR Therapeutics company evaluation covering CASGEVY, in-vivo editing, pipeline optionality, cash runway, commercialization, clinical risk, dilution, and valuation framework.
OpenADMA is profitable and ASCENIV is still growing, but Q1 2026 reset the story: standard IG pricing pressure, distributor timing, BIVIGAM weakness, and long-term guidance withdrawal turned 2026 into a proof year.
OpenAclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenTag facets appear after tag usage counts are rebuilt.